Jonathan Mark Hopper Sells 10,000 Shares of Vericel (NASDAQ:VCEL) Stock

Vericel Corporation (NASDAQ:VCEL) insider Jonathan Mark Hopper sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $45.00, for a total value of $450,000.00. Following the transaction, the insider owned 75,753 shares of the company’s stock, valued at $3,408,885. This trade represents a 11.66% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Jonathan Mark Hopper also recently made the following trade(s):

• On Thursday, April 2nd, Jonathan Mark Hopper sold 3,472 shares of Vericel stock. The shares were sold at an average price of $35.00, for a total value of $121,520.00.

Vericel Price Performance

Vericel stock opened at $45.15 on Thursday. The firm has a market capitalization of $2.31 billion, a P/E ratio of 107.50 and a beta of 1.06. The stock has a fifty day moving average price of $36.69 and a two-hundred day moving average price of $35.95. Vericel Corporation has a 52-week low of $28.95 and a 52-week high of $46.62.

Vericel (NASDAQ:VCEL) last issued its earnings results on Thursday, May 7th. The biotechnology company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.03. Vericel had a net margin of 7.35% and a return on equity of 6.41%. The company had revenue of $68.43 million for the quarter, compared to the consensus estimate of $63.68 million. During the same quarter in the previous year, the company earned ($0.23) EPS. The firm’s revenue for the quarter was up 30.1% compared to the same quarter last year. On average, equities research analysts predict that Vericel Corporation will post 0.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Wall Street Zen cut shares of Vericel from a “buy” rating to a “hold” rating in a research note on Sunday, June 14th. Truist Financial dropped their price target on Vericel from $48.00 to $42.00 and set a “buy” rating for the company in a report on Wednesday, April 15th. Weiss Ratings upgraded Vericel from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 16th. Leerink Partners reissued an “outperform” rating and issued a $46.00 price objective on shares of Vericel in a research note on Tuesday, March 10th. Finally, HC Wainwright restated a “buy” rating and set a $64.00 target price on shares of Vericel in a report on Friday, May 8th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Vericel presently has an average rating of “Hold” and an average price target of $52.50.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Glenmede Trust Co. NA boosted its position in Vericel by 18.4% in the 1st quarter. Glenmede Trust Co. NA now owns 15,097 shares of the biotechnology company’s stock valued at $486,000 after buying an additional 2,348 shares during the last quarter. Bank of America Corp DE raised its position in shares of Vericel by 19.7% during the first quarter. Bank of America Corp DE now owns 1,098,771 shares of the biotechnology company’s stock worth $35,347,000 after acquiring an additional 180,761 shares during the last quarter. California State Teachers Retirement System raised its position in shares of Vericel by 26.3% during the first quarter. California State Teachers Retirement System now owns 61,233 shares of the biotechnology company’s stock worth $1,970,000 after acquiring an additional 12,767 shares during the last quarter. Rice Hall James & Associates LLC lifted its stake in shares of Vericel by 1.6% during the first quarter. Rice Hall James & Associates LLC now owns 132,063 shares of the biotechnology company’s stock valued at $4,248,000 after acquiring an additional 2,094 shares during the period. Finally, Renaissance Technologies LLC acquired a new position in shares of Vericel during the first quarter valued at $405,000.

Vericel Company Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.